Oligometastasis Clinical Trials

15 recruiting

Oligometastasis Trials at a Glance

15 actively recruiting trials for oligometastasis are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Not Applicable with 5 trials, with the heaviest enrollment activity in Houston, Durham, and Cleveland. Lead sponsors running oligometastasis studies include Istituto Clinico Humanitas, Sun Yat-sen University, and European Organisation for Research and Treatment of Cancer - EORTC.

Browse oligometastasis trials by phase

Treatments under study

About Oligometastasis Clinical Trials

Looking for clinical trials for Oligometastasis? There are currently 15 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Oligometastasis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Oligometastasis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Not Applicable

Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA

Bladder CancerOligometastasisUrothelial Carcinoma (UC)
Istituto Clinico Humanitas44 enrolled1 locationNCT07413523
Recruiting
Phase 2

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

Stage IV Esophageal Cancer AJCC v7Stage IV Gastric Cancer AJCC v7Gastric Adenocarcinoma+2 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT03161522
Recruiting
Phase 2Phase 3

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

Prostate CancerMetastatic Prostate CancerOligometastasis+3 more
VA Office of Research and Development464 enrolled20 locationsNCT04787744
Recruiting
Phase 1

Trial of Oligometastasis SBRT With Immediate, Simulation-Free Treatment Delivery (OLIGO-SWIFT)

Oligometastatic DiseaseOligometastasis
Case Comprehensive Cancer Center15 enrolled1 locationNCT07079098
Recruiting

stereOtactic Body RadIothErapy for exTracranial oligomeTastAtic Breast Cancer: Multi Institutional Retrospective Database

Breast CancerOligometastasis
Istituto Clinico Humanitas300 enrolled28 locationsNCT07397585
Recruiting
Phase 3

Metastasis-directed Therapy for Oligometastases of Breast Cancer

Breast CancerMetastatic Breast CancerOligometastasis
Tokyo Medical and Dental University340 enrolled1 locationNCT06135714
Recruiting

Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry

Metastatic CancerOligometastasis
Duke University300 enrolled5 locationsNCT04085029
Recruiting
Phase 3

Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial

Prostate CancerLung CancerColo-rectal Cancer+1 more
Roswell Park Cancer Institute800 enrolled1 locationNCT06563388
Recruiting

SMC Radiation Oncology SABR Cohort for Oligometastasis

OligometastasisctDNAPatient-Reported Outcomes (PRO)+2 more
Samsung Medical Center60 enrolled1 locationNCT07121335
Recruiting

Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma

Lung CancerAdvanced Hepatocellular CarcinomaOligometastasis+2 more
Sun Yat-sen University470 enrolled1 locationNCT06644430
Recruiting
Not Applicable

Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)

Esophageal CancerPancreatic CancerGastric Cancer+12 more
European Organisation for Research and Treatment of Cancer - EORTC200 enrolled13 locationsNCT04498767
Recruiting
Not Applicable

Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma

Advanced Hepatocellular CarcinomaOligometastasisAblation+2 more
Sun Yat-sen University60 enrolled1 locationNCT06550921
Recruiting
Phase 3

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

Prostate CancerMetastatic CancerProstate Cancer Metastatic+4 more
Universitaire Ziekenhuizen KU Leuven873 enrolled1 locationNCT05352178
Recruiting
Not Applicable

Radical Local vs. Palliative Therapy for Breast Cancer Patientts With Ipsilateral Humerus or Sternum Oligometastasis

Breast CancerOligometastasis
xuexin he183 enrolled4 locationsNCT04158843
Recruiting
Not Applicable

Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac

Breast CancerLiver CancerEsophageal Cancer+4 more
University Hospital Tuebingen472 enrolled1 locationNCT04172753